Biotech IV Monitor

ALNY — Alnylam Pharmaceuticals Inc.

$32.5B market cap · 8 upcoming readouts tracked

Clinical trial readout dates for Alnylam Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2027.

Next readoutApril 2027in ~5 months
Upcoming readouts82 Phase 3
Market cap$32.5B
Cash & investments$3.59Bas of Sep 30, 2026
Recent 8-K filings2latest 2026-11-05

Upcoming readouts

Phase 1/2 ALN-2232
Obesity · NCT07463846
April 2027
Recruiting
Phase 2 ALN-4324
Type 2 Diabetes Mellitus (T2DM) · NCT07465224
May 2027
Ongoing
Phase 2 ALN-6400
Von Willebrand Disease (VWD); Heavy Menstrual Bleeding (HMB) · NCT07575308
June 2027
Recruiting
Phase 2 ALN-APP
Cerebral Amyloid Angiopathy · NCT06393712
August 2027
Ongoing
Phase 1/2 ALN-4324
Obese or Overweight Healthy Volunteers; Type 2 Diabetes Mellitus (T2DM) · NCT06845202
August 2027
Ongoing
Phase 3 Nucresiran
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN · NCT07223203
December 2027
Recruiting
Phase 1/2 ALN-6400
Hereditary Hemorrhagic Telangiectasia · NCT06659640
January 2028
Ongoing
Phase 3 Vutrisiran
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy · NCT06679946
March 2028
Enrolling

Cash position

Alnylam Pharmaceuticals Inc. reported $3.59B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). It reported net income of $2.17B for that quarter.

Recent SEC filings

8-K Other Events — often topline trial data2026-11-05
8-K Results of Operations — earnings, may carry pipeline updates2026-10-29

Companies working on similar indications

Discussion

No messages yet. If you follow ALNY, you can start the conversation.
Track ALNY in real time
See live implied volatility for ALNY and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on ALNY
Contact — questions or corrections about ALNY: dukeupt@gmail.com